NEW YORK ─ Marlborough, Massachusetts-based Hologic announced after the close of the market on Tuesday that it will acquire molecular diagnostics firm Biotheranostics for approximately $230 million.
San Diego-based Biotheranostics develops and provides diagnostic, prognostic, and predictive tests that support physicians in the treatment of cancer patients.
The company offers testing services through a CLIA-certified, CAP-accredited laboratory that is directly licensed or otherwise authorized to perform testing in all 50 US states, Hologic said.